Now, I've been following NUMINUS for quite some time. From the time it started trading in May till now. As you can see on the chart the stock price was just shortly above 1,5 $ in May. That may have been an unrealistic price given what they had
accomplished at the time. The market value of the company was at that peak around 125 million $. Now Oregon just legalized psilocybin assisted therapy and they will need two years to lay down a framework of how to implement it properly. This is very big for the sector in itself. Since May NUMINUS has made many significant improvements. They now have a health Canada license to research, grow, sell and distribute psilocybin mushrooms. On top of that they have added some very big profiles in the industry to their team. The single most important addition is in my opinion Dennis McKenna. He is well known in the industry and he has conducted research for decades (he is on the advisory board). If this sector evolves with more and more states legalizing psilocybin therapy and perhaps Canada legalizing psilocybin therapy, there will automatically be a need for precise dosing of psilocybin. It is not optimal to administer a dose of actual mushrooms because the dosing can vary even though the therapists may have an idea of the strength of the mushrooms. See this is where it gets interesting because NUMINUS is conducting research to find a way to extract psilocybin from the mushrooms as well as other compounds in the mushrooms that may have other benefits. I like to compare this scenario to extracting THC and CBD from cannabis even though this is very different of course. Just weeks ago NUMINUS announced that they were the first public Canadian company to harvest "magic mushrooms" legally, therefore the research has begun. The company is way ahead of its competitors in some areas. Back to the stock price, we're now trading at around 0,45 $ with a market cap of around 50 million $. Given the recent developments, I think there is room to reach 0,8 $ pr. share in the short term. In the long term I don't even want to guess what the stock price can reach. If this market starts to take a bite of the huge antidepressant market and other markets as well (we don't yet know all the use cases for psilocybin therapy), there is absolutely no reason why this couldn't reach a market cap of around 500 million $ within two years, given of course that we see positive news along the way. Finally, if you're thinking about getting exposure in the psychedelic sector this may very well be the best/cheapest option with enormous upside potential. If you have any questions, let me know.
- Emil Ramsby Rasmussen
accomplished at the time. The market value of the company was at that peak around 125 million $. Now Oregon just legalized psilocybin assisted therapy and they will need two years to lay down a framework of how to implement it properly. This is very big for the sector in itself. Since May NUMINUS has made many significant improvements. They now have a health Canada license to research, grow, sell and distribute psilocybin mushrooms. On top of that they have added some very big profiles in the industry to their team. The single most important addition is in my opinion Dennis McKenna. He is well known in the industry and he has conducted research for decades (he is on the advisory board). If this sector evolves with more and more states legalizing psilocybin therapy and perhaps Canada legalizing psilocybin therapy, there will automatically be a need for precise dosing of psilocybin. It is not optimal to administer a dose of actual mushrooms because the dosing can vary even though the therapists may have an idea of the strength of the mushrooms. See this is where it gets interesting because NUMINUS is conducting research to find a way to extract psilocybin from the mushrooms as well as other compounds in the mushrooms that may have other benefits. I like to compare this scenario to extracting THC and CBD from cannabis even though this is very different of course. Just weeks ago NUMINUS announced that they were the first public Canadian company to harvest "magic mushrooms" legally, therefore the research has begun. The company is way ahead of its competitors in some areas. Back to the stock price, we're now trading at around 0,45 $ with a market cap of around 50 million $. Given the recent developments, I think there is room to reach 0,8 $ pr. share in the short term. In the long term I don't even want to guess what the stock price can reach. If this market starts to take a bite of the huge antidepressant market and other markets as well (we don't yet know all the use cases for psilocybin therapy), there is absolutely no reason why this couldn't reach a market cap of around 500 million $ within two years, given of course that we see positive news along the way. Finally, if you're thinking about getting exposure in the psychedelic sector this may very well be the best/cheapest option with enormous upside potential. If you have any questions, let me know.
- Emil Ramsby Rasmussen